"{\"eval_set_result_id\":\"capricorn_adk_agent_quickstart_eval_1754693698.710449\",\"eval_set_result_name\":\"capricorn_adk_agent_quickstart_eval_1754693698.710449\",\"eval_set_id\":\"quickstart_eval\",\"eval_case_results\":[{\"eval_set_file\":\"quickstart_eval\",\"eval_set_id\":\"quickstart_eval\",\"eval_id\":\"simple\",\"final_eval_status\":1,\"eval_metric_results\":null,\"overall_eval_metric_results\":[{\"metric_name\":\"tool_trajectory_avg_score\",\"threshold\":0.4,\"judge_model_options\":null,\"score\":1.0,\"eval_status\":1},{\"metric_name\":\"response_match_score\",\"threshold\":0.4,\"judge_model_options\":null,\"score\":0.6616871704745166,\"eval_status\":1}],\"eval_metric_result_per_invocation\":[{\"actual_invocation\":{\"invocation_id\":\"e-491754ee-4b07-4f17-982e-cb9af50246db\",\"user_content\":{\"parts\":[{\"video_metadata\":null,\"thought\":null,\"inline_data\":null,\"file_data\":null,\"thought_signature\":null,\"code_execution_result\":null,\"executable_code\":null,\"function_call\":null,\"function_response\":null,\"text\":\"45-year-old female with invasive\\nductal carcinoma, ER+/PR+/HER2-,\\nBRCA1 mutation, T2N1M0\"}],\"role\":\"user\"},\"final_response\":{\"parts\":[{\"video_metadata\":null,\"thought\":null,\"inline_data\":null,\"file_data\":null,\"thought_signature\":\"CuEaAVSoXO6aRzHoQqC1nwf_Pgak7SX0Uh_a2HisGbZdrLPEkrl54xLe-ruJPqIBIpvAYqTXcWmMOQ16gYKEKQWNaOgKIa8CJr3V6ejuMBspKD0OSkiKlgQA1LLd52JKXYV5tx2YFybmieTmcLFmyPNhNbvfxww25fOuG90uRvWM8KdqsPcPMKFRQ7-2iv8dxckPO_kBj2CDisJurFkinbKox2pSz419zbeKUKbp6zkKShaKzgBh1SaZtFv_njHMIwwmah6pn5usUQwLfCPonun7EA4ChYdQaksSN03_EMoiCfqAXh-kEkwPM6DlVzE8JJdjCU2dc-W0RhlM68JK-CWgs7RDz7z6ABPjV5yyyoW79LTAlIvfwDvKD7-BjFwlSPZ0I1wzgMoya8d6jf9ZrTOfmxxfHJmWK_9IApB3XdMfv88yMOCj-LjUD4JulvNtgi4rcaGmjAXU-kmFkEp7yVXewrqZ-OZfsPLXKeUFRJ2sn-v6M-1Rp_K3xlXrM6qBGlbGedtyamqzXVDyS-ws-7oL2dMd2TwIu-_WIqzHWi2vCwu6eQyime6i7PJfqZ8Bn4DC2nQ-LYHxLTeuVuCTBAN8fHBeopUZSNFWIpkfYEi65tepzEpHwAMeZybsjtlk2S4WvXR-pRno_vh3r3ulNq8BG94wsqX-H6IOR7tOPTS2aBLTHXvu0il5YGhLO0NlIHXx31KaP5QkGlx9S3LERMGoCnwzJSeM-OZi9hC2G546Xhf0ZryIKmuwsGD9wMEAWGz7szzwFXrGiP_TXXWN_h4J9PS_3ZHNMXxLlCVIr6xcwLWVVUk22PHgHzrmzfouhfTFrs8HpoYrkvdMiNebDseZS81mWzTWx6HyYEaxjBZtmmZ-3uRHA3ST1ylqOBTMoGpvJWjRbpW1jzcSuS5GlRqpv7ArQu0tu6LeZUMup-_9XTE1KKJo-uUM4pAAUdH-HuLMIbDa0Q6gvIgBq7Jp03n3DtH00f2SIC8P-490WQipLXnyKt1ChtvJS-eHZZv-t0kgEAZ6cYF6RYnfUuxOOQMqosukSGs6z2NLEy4nLM_CZPrOOrnQSeHUYYAQuhr6Kfp_mhRZsY-vmcKdZ4U4j6XK0srapCP5C91HuP1pz-_NLzUaO7rz3AU35KzcMlsPoBWnJuQDWpOnygEu62TM8NQDRLPw44xuBNZQBpJFex9YUjZzyfrxrFH98CJuoQjI3HC93VMKdOb7WA-YrutA2eXvvw4ERrKik7J2KhtkkFVUNMZgIoY7B1txrkWnpQD3FaIhWjz6xdVNx5ldcfMTXc_QNp1IdwmMiityjRAux9CRv5T8V8xOyGqkeVXZXHA83cCE4xt0gxTl1X5UjtZ8EsJHRw9FugTP9mtn5ljNLVYmhlTGamV6u_UwXq-RlcUsgXSvvwik4S0xTM9_2Nr94zLkYYYv49k8fvIBa7i8twxjJ5_4pNDPidoA4I4nvymbUL9d0h9rAFjyUFvrjyNDkhhduq429D7gyMFVUxVOSnYRp_lfyO54x-A3bvucYFmiuWru_BkDqhk7ZHMCcWfDNyEOhJRuD1dkKe12PZr4fhy7eMkWp0Mqnnnb0nIO6cON5Hb2yfRxlOopC8tV30PM_px3Aw5oMSd0sayxM-0H5msNjxnMBKfW9LoCkhSBKkGklNG-LQ_3PJEtxZXTkyQAhHLxWE8kx1mJQ4ahTfdlaJ2VtSdbLCPcRSDPi3ekxdF63zS-swRG_-ca8hCoGFUU1U4Xi8pednWDKMWbdvo-PNxrgyLYJVRkdM4aHa44NvBg800P1Tp52HzSmPcERdNHXtWE7LUHiQwnHhANRkJ7v_3cFFv0xf-3-QMUbMnUcnDOOLJGm7dS-SBBMg-9pozCf7TWwUE-HedkwetEy78DAM4_tSQ3DDu9Y6sVSyxhr2u8k40p-EfQbkStPniWfzpizPqWF7jkZOX-xE3gp22TFsyRsrX2-l-bvXxroBkRR0pwDnE038H7dtt0klwXwNdKIoG0kXxqFbPG9u73Mg87nvZa5sFe4Ia09nmXDGJQbKSi47Qnne52Flv-e6wBH6K-fqi73S7xV8t54omDZdgBMbaQtLic4uOrAwcmXA0mMem-j_FXswm5NLtZjqOEInd3S2AGvIreHr5zVbN8J-UmYlU6Lkro-n18OW7S12kEBe6REd4Lcdy5J4tLCqRZ419Mqv2h6p6O9dbvGcnaceuwugsJ1yklTsnTiAXSwoTSHQ9k74uF3OxWZMNwxosHjgheie-Yevy1sOIRTBfTOjV9sjiHvlxIa0bF9KEGX6jE1g0PUB_E8TWoNAungIzeqP-3Y6xZgSjepFufpX2eFIX3KKJt-Eagu1oSQViGObh4omeaYpXFs2MImXioGm8BjGm-1KkdxdnhzoNJUtQRvY6f6OaFBikuvfiUxNyu3tnaetASmV3NNt_dLdru8IIDeP9N_q3pWBWsolx4pa_uLmeslXOXkoEvGkLOyBeaE5hB7kPWqSXhob0PTJUIfCSW5433WJW7ouTzp6ZO-j3TwYfgKzi5tfrpHyXxD--xL5EJc3cTY2v4h8jezUPsQDBH2x46Yxf-dOFokaq4gBitulJd1QpVnVS943Y0Tmfr-ne6sY1FfAolVXLTemM-J6grzFiYSXXKvdCY7NU8qX1nmASgWkwmPvv0OhNnTCBQU893IdybBeIQP8poKC8KfLUauxEAQbP292ebIIA1BjiVVb1d3MvhJTi6rm9vfkaMMX23T1WfoI4u0Wv-aKnDDXrMVFivSFaDE8nuapcui0KqraEeUNrL72TRsapTe9Olc36u8x1VyCcWtc3SxuOm4HCah_v1KHTpnvZUnQxwJ1u8-T6Qpab_8yxaeNlZrhETGk2vFl9Q1xCRBOWVXP95LaUjnjKsZaxkJZ3RgbZWADb6WIQbuuRa6ISaAebJj22Jd5N7mQDyduXXX868ipDabT2r0mIWYVTo4ZiEaZ8JEPX89zACeksz724FcNNN5ZoWnItuuUB6k8gKSPGy1t1jD7PKIlZ9XOrA54OXS9JUNh5SDSY4QVjD2LjG1pbCBry8MsmIo9CuifPD714CDSMHq8MH7E87Z33gTkvU7pVixR2HK53C8339gnXf5fulcjtmgIhFZ34wZgdeCx68wcN6goS5lcEainMcmFKoqvMLeVbtmWE5RJySMJCIqiuL2QwznZyh2whhTMLb6ggM4_fJnfwKvLrdXEYHIVIYO4GOfkMjilSrrOK61pdMt0IQfcz39tr0Y7PQ8aQJgHPUZrdFl8R5cwGQi7BYEO8jZVk8PpzhZbDN113GGcZGjka8AmqUZNbvmrrV-qq3f7u6rwlAeV6Es7QwnfgDRE8zC9-06inXAL4tpW98kqYsZ5oOn5hvztHy6xPqaYE0tKwVMliq1TBTzpI9Ar_ZtY0am7yOitCJ2d1J7G7mFo3dKJng6ww5YiqM7EKXpReIXKgksq6S_kcsyL5781TOuguapVshAEe3DZTICJ5s5DzBJtYcMbA8up5RXkKjO6fPcA7HKzyfCemONLbNUcmabHmLsIXHAvRGxnWmpH061J_dL00RUd_QpF4X8uuhELSu87LYHzIOGT35lKRb6sGlijSefTZ1jdiCDdVAZ2nsonn8VWFVTZ_3lJOTvpGrQCFZ9Y7ISiuTTB5M9wpUVCh2z8sduXrGN0r8T_q8qeBdCssJBr-a8cASCNMH-W1NHOmqEYS-EMH-KivEPRRONrzbKAocunDLhM3ERqoANXDpRZjmWDU_AMRhvGK1kyyNEqBXMpE6LG7r9CAEomBU8-7XRqkYde-TybfQ9nJnYGBtXM9wHDMlKhU6d4CxZD7PWNykPKh-i1RABv5RWG_3VlPDLUAgQEZV1ImbqzGw6gJQlPvQlXx5N_2k5wLnNTCYPx4TWpE9PusIeIQColzpQqpL9CIexHK-xEUDNS_6iCXyBw8ZeC1gYV-MoCE66hd4LmPHgt1714c7B-IYFENxpG1shk3G1iK1V4T_aqr5onZCGsuApLpjarum7ckHQJEnkP6sOcRdLOfKh7Jixzg038ndF1v_N_xsq2HqOTxfbelLBXcBcxFNyh8lvj4G_wOFJph6FC5J-28ZlnEOAZhLMBRxOTC1V8Royo4-BvUOPe_ajQmpcrRGJNgSdZ182KWAY64ypsNbsr9UQB80G7Bgix1TyOpXopJ__tA82Ag3AvG0jgevUggoOFoCFlymzTt6tRAsCRbPbvZZdzvxBsk1LEARXLkdMAw5URHYGdE4kF6-8okK3Py70pVDd_EKWVcLO9w6JQIYd42Mou4TYbWR-ADKi-yAwTpr4dasngOWHAr67M5Ck79zGoI8GIrk0uW_QjgxjRxCNCLM6v0PpIyR6HHh6LimJqvHNZIId7Z0NKuaEbgD-wz657UkidsjgljdPPfPkhPD9XcchiisCplmuFWnFMoFUJ4aigOYg2YuC4U8BKbofxCIN_k-i3fwcZSeL1YO7UKdImLxUrVTfZBqng-2LTqtCyZBpEaFcVM2OYT8GAHgmsRUBYpwX01oj5PQ68Fs9evFGQkp4Ipzhpw0Iny2r9M=\",\"code_execution_result\":null,\"executable_code\":null,\"function_call\":null,\"function_response\":null,\"text\":\"Analysis Results\\nCase Analysis: Stage IIB, ER+/PR+/HER2- Invasive Ductal Carcinoma with Germline BRCA1 Mutation\\n1. Case Summary\\nThe patient is a 45-year-old female diagnosed with Stage IIB (T2N1M0) invasive ductal carcinoma of the breast. The tumor is hormone receptor-positive (ER+/PR+) and HER2-negative. Germline genetic testing revealed a pathogenic mutation in the BRCA1 gene. This combination of factors (hormone sensitivity, DNA repair deficiency via BRCA1 mutation, and node-positive disease) provides multiple avenues for targeted adjuvant therapy aimed at reducing the risk of recurrence.\\n\\n2. Actionable Events Analysis\\n| EventType | Genetic/Clinical | Explanation | Targetable | Prognostic Value |\\n| :--- | :--- | :--- | :--- | :--- |\\n| **ER/PR Positive** | Clinical | The tumor expresses estrogen and progesterone receptors, indicating that its growth is driven by hormones. | Yes, with endocrine therapy (e.g., Aromatase Inhibitors, SERMs, OFS). | Favorable; predicts benefit from endocrine therapy. |\\n| **Germline BRCA1 Mutation** | Genetic | A pathogenic mutation in the BRCA1 gene impairs the homologous recombination repair (HRR) pathway for DNA damage. | Yes, with PARP inhibitors (e.g., Olaparib). | Unfavorable; associated with higher risk of recurrence and new primary cancers (breast, ovarian). Predicts sensitivity to PARP inhibitors and platinum-based chemotherapy. |\\n| **N1 (Node Positive)** | Clinical | Presence of cancer in 1-3 axillary lymph nodes, indicating regional spread. | Yes, indicates need for systemic adjuvant therapy (chemotherapy, targeted therapy). | Unfavorable; a key indicator of higher recurrence risk, justifying more aggressive adjuvant treatment. |\\n\\n***\\n\\n**Interpretation:** This is a high-risk, localized breast cancer defined by two key targetable biological features. The ER/PR positivity makes the cancer susceptible to hormone-blocking agents, a cornerstone of therapy. The germline BRCA1 mutation creates a specific vulnerability in the tumor's DNA repair machinery, which can be exploited by PARP inhibitors. The node-positive status (N1) elevates the risk of recurrence and confirms the need for comprehensive adjuvant systemic therapy, including chemotherapy, to be followed by targeted agents. The treatment strategy must address both the hormone-driven growth and the underlying DNA repair defect.\\n\\n3. Treatment Options\\n| Event | Treatment | Evidence | Evidence Summary | Previous Response | Warnings |\\n| :--- | :--- | :--- | :--- | :--- | :--- |\\n| **Germline BRCA1 Mutation** | Adjuvant Olaparib | [Tutt ANJ et al., 2021 [PubMed](https://pubmed.ncbi.nlm.nih.gov/34115795/)] | The Phase 3 OlympiA trial showed that for patients with germline BRCA1/2 mutations and high-risk HER2- early breast cancer, 1 year of adjuvant olaparib after (neo)adjuvant chemotherapy and local treatment significantly improved invasive and distant disease-free survival compared to placebo. At 3.5 years, the invasive disease-free survival was 82.7% vs. 75.4%. | N/A (adjuvant setting) | Anemia, neutropenia, fatigue, nausea. Small risk of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). |\\n| **ER/PR Positive** | Endocrine Therapy (e.g., Aromatase Inhibitor or Tamoxifen) + Ovarian Function Suppression (OFS) | [Francis PA et al., 2018 [PubMed](https://pubmed.ncbi.nlm.nih.gov/30575488/)] | The SOFT and TEXT trials demonstrated that for premenopausal women, adding OFS to either tamoxifen or an aromatase inhibitor (exemestane) significantly improved disease-free survival compared to tamoxifen alone. The benefit was most pronounced in patients who required chemotherapy, such as this one. | N/A (adjuvant setting) | Menopausal symptoms (hot flashes, vaginal dryness), arthralgias (with AIs), risk of endometrial cancer and VTE (with tamoxifen), bone density loss. |\\n| **ER/PR Positive & High-Risk Features (N1)** | Adjuvant Abemaciclib + Endocrine Therapy | [Johnston SRD et al., 2023 [PubMed](https://pubmed.ncbi.nlm.nih.gov/36877088/)] | The Phase 3 monarchE trial showed that for patients with high-risk, node-positive, HR+/HER2- early breast cancer, adding 2 years of abemaciclib to standard endocrine therapy significantly improved invasive disease-free and distant relapse-free survival. At 4 years, the absolute benefit in IDFS was 6.4%. | N/A (adjuvant setting) | Diarrhea, neutropenia, fatigue, abdominal pain, liver enzyme elevation. Requires monitoring of blood counts and liver function. |\\n\\n***\\n\\n**Clinical Perspective:** The standard of care for this patient involves a multimodal adjuvant approach following definitive surgery and likely anthracycline/taxane-based chemotherapy. Based on the landmark OlympiA trial, one year of adjuvant olaparib is strongly recommended to target the BRCA1-mutated cancer cells. Concurrently and sequentially, endocrine therapy is critical. Given the patient's age (45, likely premenopausal) and high-risk status, ovarian function suppression combined with an aromatase inhibitor would be a standard and effective endocrine backbone. The role of adjuvant abemaciclib is also a key consideration. While the patient meets the node-positive criterion for monarchE, guidelines suggest choosing between a PARP inhibitor or a CDK4/6 inhibitor in this setting, as concurrent use outside of a clinical trial is not established. Given the germline BRCA1 mutation is a powerful oncogenic driver, prioritizing olaparib is a very common and evidence-based strategy.\\n\\n4. Multi-Target Opportunities\\n| Treatment Combination | Targeted Events | Evidence | Summary |\\n| :--- | :--- | :--- | :--- |\\n| **Olaparib (Adjuvant) + Endocrine Therapy + OFS** | Germline BRCA1 Mutation, ER/PR Positive status | [Tutt ANJ et al., 2021 [PubMed](https://pubmed.ncbi.nlm.nih.gov/34115795/)], [Francis PA et al., 2018 [PubMed](https://pubmed.ncbi.nlm.nih.gov/30575488/)] | This represents the standard-of-care, evidence-based adjuvant regimen. Olaparib targets the DNA repair deficiency, while endocrine therapy with OFS suppresses the hormonal growth signals. These treatments have different mechanisms of action and address the two main vulnerabilities of the tumor. |\\n| **Abemaciclib (Adjuvant) + Endocrine Therapy + OFS** | ER/PR Positive status, High-Risk (N1) | [Johnston SRD et al., 2023 [PubMed](https://pubmed.ncbi.nlm.nih.gov/36877088/)] | This is an alternative high-intensity adjuvant regimen. Abemaciclib targets the cell cycle by inhibiting CDK4/6, which is often dysregulated in ER+ breast cancer. This would be a primary consideration if the patient did not have a BRCA1 mutation. |\\n\\n***\\n\\n**Analysis:** The most rational and evidence-based strategy is to combine therapies that target the distinct biological drivers of this cancer. The combination of adjuvant olaparib with endocrine therapy (with OFS) is well-supported by Level 1 evidence from separate, large, randomized clinical trials. Olaparib addresses the germline-driven risk, while endocrine therapy addresses the hormone-driven risk. There is no high-level evidence to support the concurrent use of olaparib and abemaciclib in the adjuvant setting, and the potential for overlapping toxicities (e.g., hematologic) would be a significant concern. Therefore, the decision is typically a choice between these two agents to add to the endocrine backbone. In a BRCA1-mutated patient, olaparib is the more direct and targeted approach.\\n\\n***\\n\\n### References\\n\\n1.  Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., ... & Roch\u00e9, H. (2021). Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. *New England Journal of Medicine*, *384*(25), 2394\u20132405. [PMID: 34115795](https://pubmed.ncbi.nlm.nih.gov/34115795/)\\n2.  Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M., L\u00e1ng, I., ... & SOFT and TEXT Investigators and the International Breast Cancer Study Group. (2018). Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. *New England Journal of Medicine*, *379*(2), 122-137. [PMID: 30575488](https://pubmed.ncbi.nlm.nih.gov/30575488/)\\n3.  Johnston, S. R. D., Toi, M., O'Shaughnessy, J., Rastogi, P., a Comet, A., Prito, B., ... & monarchE Committee Members. (2023). Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer: results from a preplanned overall survival interim analysis of the monarchE trial. *The Lancet Oncology*, *24*(1), 77\u201390. [PMID: 36877088](https://pubmed.ncbi.nlm.nih.gov/36877088/)\\n\\n***\\n\\n**Disclaimer:** This report is for informational and research purposes only and does not constitute medical advice. The information provided is based on the patient data supplied and a review of current medical literature and guidelines. All clinical decisions must be made by a qualified clinician in the context of a multidisciplinary tumor board review, taking into account the full clinical picture and the patient's individual circumstances and preferences.\"}],\"role\":\"model\"},\"intermediate_data\":{\"tool_uses\":[],\"intermediate_responses\":[]},\"creation_timestamp\":0.0},\"expected_invocation\":{\"invocation_id\":\"e-ae5ccab6-6c5f-4d71-af28-cbe466f4bb35\",\"user_content\":{\"parts\":[{\"video_metadata\":null,\"thought\":null,\"inline_data\":null,\"file_data\":null,\"thought_signature\":null,\"code_execution_result\":null,\"executable_code\":null,\"function_call\":null,\"function_response\":null,\"text\":\"45-year-old female with invasive\\nductal carcinoma, ER+/PR+/HER2-,\\nBRCA1 mutation, T2N1M0\"}],\"role\":\"user\"},\"final_response\":{\"parts\":[{\"video_metadata\":null,\"thought\":null,\"inline_data\":null,\"file_data\":null,\"thought_signature\":\"Cs8bAVSoXO61CxK-5QoaihFRovk-NUxxk9lYX2dOPDXRPeYD4pqv6qE31UCnnPsvxYJR688sunwH9mGJ4QIOfW6akze2JMMoQwW9YeBow3B1IClLN1IVswupu5Cs8J8EGRM7h_XsLY1xRcelfE0B21l3GlbL9HK7hr7TD11IERfzlGSWovW8GkrapIOKosDlIqKbTJ2BIae1pBxh6R9QZhSHu_S1SZAdDr0GMM_bkMyI23PUoNBa31rcwVKyFGZzR8--iBliCccRvGIKTApgoz27KyxyYzvVxnuZFXlrD7d4VjgXVM9KW_UMqnPFkDTGIkZD-8sRxeW5E0VOh88XG4gy61MoCLYHkegvr9bm23hc9vl14pg029lvlZ6FkIemb9yELe6qvtp-RD6In6T30655ZGXGWjfiQ_Hfmu0aBMq7TUiBr4OjQ_FUDwVA614AlTesv6VDtT4Ia_HapDDfAOe4w07ReKe4gjfpREKB8PrtKDWAzDSe9RWznRODDiWYgvP6KsTYuHkSf8lBd3DpqHapIdCuUfgUVrI-m6RZu1I66BDSDjeLHd6HaIuuMq-CAkxR9GHQhgCvY7hRUZ54S9wmPECwLMpxqoNzlJemZ9EL-WZu6UC9hMsSn2g6CmY7_CJM7Exuyeez8Z8DgCzmC6AQ0B78gJF8FgoZzIrRPSXyNnjRh0ZTcqHU1vm1IafkFRxuftepV99DzTZAqu2LkMG6mVF5rihFejGZtMhUn5Ls0CciyHJidnjdJHW1e0sSXPDQWM-EA7iSi0ufFLobvk2J35rhcZb8QY08MXeZlTw5VnQ_nFj5u2j0DpL1h-JUB6iaIQbOur2OyxtjCr13vkjMVjg4evcbiYc5F1bef4db3gXhOzrLTYGjvMM1HLcnRiKsf7zoH0XGDwp_zprBy8pts2qzRvg7_Diu60Fws1--cJLPAHm_m_YCcrONyHmJ7GOTiCDm7HX58GJxwguh-IeOlbn2Ak-zKpvp-3q0R3MQ6nrH7IOHj1gDqVgZoKTy6eCnLXQGwnJS3xze1ak1kZUizncI3LNaHw9cbM_WBWLVm30_wu3lRwibHKtFbfyXXJKzBJStrWQJgwO8c88Tk4eUl3_BjdGKaNoIj_k8kSgLwfS5J8PEHRQqW9cexCv9VNRt1Z4MX5ybmCQdcnmggUneEvNtuGhsHtipPtXl8RKCDscvHpmgd8d69eoySDMV-fn-gaNxosMs5QNO1pahPUtmTwd6VnjFGxonbsoX7V2iyBx41znEhQCg6BHu9zaVCbjqTanyknvk0BKpVPW6Dwt9aXCXIi1k6QSn5WKHWhOkKqu512Gi-K_kX-M7VLdN6Xb-P672yjtSMmBiJ2s9xAuispQpfb3ovxsEryfv_z2i7mcwJPW_5ceit3q8j7VzunP1VuJ60ObEZt1NpIvR3ZyL9aWThjhY3Y6bSD3FX6kKrtqYEh1C9XB_EPMKobcOfM4oikKWPK5A-X1OyjzaZ_ED0do4q0VfSwZgmYOWKVXHvtuQ1H0LOcslpkSbSJG8sDnMI0KGVNH8s6FqoBRfROqziLfg7I6TEd9b2HVcF9XuCoL75VsaJN-WLgIhuNOdZ069ODb1vBfG6sFZk1_pxRzGi3w_v9cYfyZqpsy7OKuWeV3FEV64AznHnubIrL2NmcY_FWLjT6dkoNJC5vWMZIRl1m8_9YjdEezPz5g_xHTxE1qmGI5lzHPjXqCbVMCI0TW1a-IpKSw1kkJhLbb7s5X-mC6jlY130AiYPLZINhZ7QKijMv-vNOvoIjB6Ye6m3HxedQObA48TtYNtsykv3HkebtmGQeLaaJspSdWbGZWrDO4YlCui7I_Eh59SifirJQ3zS8FViNzZSOHbVW3ZNNp-ZwrVY-T1AECeeA4MUxoEpcQYA9i0SSOs8RKRgc8y3S6WIUxc9EpqZixSvlJsK5xKLgkp7HNihOolm9kW6eYB4WDFPsoNYIMskogEzGDLMMXTQJboftoAzmiqgg-ZrwTP7rdkpk4UREvl8Cx28Iv1hKXwSKfqJJrO9cahtKkyYmTPAhayLTsrEPDd6JTJPEKM4BCbWs7qg81fOa1wPHQSTbsNYWVFREwggRfu3PLigwg582epsBWGyPrGaQT_TjERuwTF_LH7Cagd9b5x32FBAwY0t5r__yW1-e5YTNN6V-__VZdke9z6ndDpuIJ3Rw61PUcuJ1uYITIr9pjiH8e0tnILsmakvKQNxN3Pdoc2EZOJm4acNJO63WfIXzKfx2ObYDdr8S_CdAvaISNAYyjzjIMOg5tJFBNSfiIsVCtDDswlfgWVP5nJpcBN99Emcr8QP3SMhBolsgF45Xwpu-YswzNX5iwM6Pc1JnQ8ri85W-jp4zEivyAbcH18mtMukbVZGyDaPfSG3EaXy62t6w03hg1nH_5jy-4pAI5zmp75sW4cFiKhEsofM-5fiaVZQ59WdKhYiZyjTQdncc9yIYN1ydqyxAuuJd65qqf2gtd80O_YnTDolFLiILrO3NHNp6gBp4mKuwmcmEIWZrkwhKAvet6yJhwkI4k3XEygDyjWRIas-25y1AWQG6H3Me0EXJ9RK0nTgk7xcJ2DnvQgmp103GUM2-HeZHFkvqsTe3GKMs0cBeXuNAk0OFUM4p8tYq2o4J9xlGL9jau83nSh7ErUq6rPEjM0W4PeA0basYfkXNuyO1Nd-j0DLEO9_WCbAaU5zwApIQaIja-exwddJ0jD1c-jgROUBOju_NF6zxk5KTAgJxgfAwro4L57q3fhpWvi5MX4W9B2qD8S89nAQdnede-5_q_MFXLjskHw0_8Tv15fswfNwzDjtfO8wvyQpVepMhBNLXuQMMM8EA94jTLknoeoZMb5m86vorA9wYHjSWRIbPcHIV26_e9RjTB8TWMduaVwXb8CACCJj5wOJFw2SwSwKOS5MucPAXQ-EKB0qMkYQ0jKsyqaQL4zau9pkEIbuUFpxHulBdyKXb6M29EjRv1ZAhdFktAul0b_Pezuz3OIoDp7H6ArLWipyn5rb9nBwAcKXvivJX3-8APye6HGcEhX6nhpomYxKTpTrBJ3Jb-ClA_Qlq3_P-iYR3YjuUW_qzwKF2GVdAyHrWPlrXGG2x99BYDSTpV42kDmQHYYarfRNpuWtT68f6FtgGiqwwfWI1ZfQhGGpNZPUFwXRRl01bQsw4hn2Nr-C_dCxwupBO0PvXeluytn2D5pKWmx3ktRE68bwYIsLEcdXH7mxjrZfkvkghNCxZSkHbHiRPR48pXjfdQ40S3sIiT2DgFU0z9ibpoS63ilZZUEhgZQcgbuQ43M9KQCb-9fUjnlyD9zJdSVEpSmL3khl-3fP89UWBDv1Bu_Ut2N7sb5-WeQHNKS_A8musqgvX5zrmY8yrIMqNdZE8bWH31geOhTWb32vy5_sRF6F5HJt00z5QpN_i4OznlmSjDI6Vh0w2AAJrZ9l6Egi6K8IwQ0vssbsNCUqfqLddeNOEg6iGYL9Ko0QzRw1bVcojMyQEjyJ_TKSVN3wNxE57wJa8YXM-_uQu65GLBiapRPkVOPOywovIox1Pj_WPsC-hWYU3ZJUYCwjhlYH74s3ynnc8MbrELXscu-on2MGmwjLHyFl622hVtCcTqPm7ob10_tC5hyq3z480lAT_EOMmsbFIGw5L0IkHckOdguz79YgFWLdD9BqvBjzmrsHpCFoOMrMMz0pOBLl_N084GPOvdFLLcHo1OV8edXMluBz7CLBnTaXMfWeS5C3C21Bxj1ZqjrW0Y6ZBVb3T--AE55oHAeppNsewkj2O6eKtOvbC7UTMvnawqVbzCaWmgABhEUoy_Nl2HR_iuX-Jot6ALXvW3PMJ4IAiI3zITv_1HJpc2X89TAwKj5zN8sBj93nB8j9kZQDYklNC0kBUprFT5eoqXUMliNFNLI1IObCQMrj9J3kk-B-EojpUTeEbg4JYAF77rBzBguLTMGSCgbUU-5X7IOH_IJmXOqkGOd8pZJFpd4HXwokPYedIh4I_JyC2SPq6q6lD14s6V3wcGz6uMYtCi3QGznBKPppUErhLqdjFtZ-XePKdlgXKkJaqtkEYo_-LujUsJeJAVJc5SFHXIMfB8df9ant3YsIygHfRNazL67CtXIVbPQq2nIU6--U-5Xzme50Khn2xWSQK5XfrMWOqIpMfArp5FE9r0nU_h4C5BKB58xiiJz8deqACm-ks62bHsc5yFEf8qnGkwgJBVUiEGZpOzyOzfrHRltjwJ6XkGeZKvmYfG_NjVq2zdf1StvDc6YyVfEWVmx8yQMTyX3ClZpJboc62ewPMbvjbc2kbdeml-WdbOIQnE_CW4h5iopy_q43TeqRAENvfDwoI1mzqpS5hZQK28sUgvoHQ8VhCWf-YlyW286nhAv90OMTesTow3WHz4aimkcHg-PCmyTBbeMEwd4dvC_oQ3pBjVr7YfOnHY5bQXqIcZRk7Dlo9-luLS7JLanq6ibDZADV4etEwkACVQec-sNZ-EmfuRjnpkfajLgEf3-y4NBLZcjBG3TZchyse_C7J2JU86nmYs83myej_nTY-kq46UrS-P0h8hsf9yR-hv8dTQ-Sc9Ewjy9XmraNrmPFJnyx_c7w4H7jV2r8m16vQ2-IV_TLw4UPwM1BxtAqCO_Fh91WQ_dEkIqFbHqrvxOeLCMJd9TEt8WsaTxIht1BK9nxjB9BgJAU0Q1vQBmOvDVEZhZwsMTuw==\",\"code_execution_result\":null,\"executable_code\":null,\"function_call\":null,\"function_response\":null,\"text\":\"Analysis Results\\nCase Analysis: ER+/PR+/HER2- Breast Cancer with Germline BRCA1 Mutation\\n1. Case Summary\\nThe patient is a 45-year-old female diagnosed with stage IIB (T2N1M0) invasive ductal carcinoma of the breast. The tumor is hormone receptor-positive (ER+/PR+) and HER2-negative. Germline genetic testing revealed a pathogenic `BRCA1` mutation. This combination of factors (hormone sensitivity, BRCA1-mutated status, and node-positive disease) defines a high-risk profile with distinct therapeutic vulnerabilities that can be targeted with specific agents. Treatment considerations will involve standard endocrine therapy, likely in combination with a CDK4/6 inhibitor, and a PARP inhibitor based on the germline mutation status.\\n\\n2. Actionable Events Analysis\\n| EventType | Genetic/Clinical | Explanation | Targetable | Prognostic Value |\\n| :--- | :--- | :--- | :--- | :--- |\\n| **ER+/PR+ Status** | Clinical | The tumor expresses estrogen and progesterone receptors, indicating its growth is driven by hormones. | Yes, with endocrine therapies (e.g., AIs, SERMs) and CDK4/6 inhibitors. | Favorable, but risk of late recurrence exists. |\\n| **Germline BRCA1 Mutation** | Genetic | A pathogenic mutation in the BRCA1 gene, leading to deficient homologous recombination repair (HRR) of DNA. | Yes, with PARP inhibitors (e.g., Olaparib, Talazoparib). | Both prognostic and predictive. Associated with higher-grade tumors but confers sensitivity to specific DNA-damaging agents and PARP inhibitors. |\\n| **N1 (Node-Positive)** | Clinical | Cancer has spread to axillary lymph nodes, classifying the patient as having high-risk early-stage disease. | No, but it informs the aggressiveness of adjuvant therapy. | A key indicator of recurrence risk and prompts consideration for more intensive adjuvant treatment regimens. |\\n\\n***\\n**Interpretation:**\\nThis patient's cancer is defined by two primary targetable pathways. The ER+/PR+ status makes it susceptible to endocrine therapy, with CDK4/6 inhibitors being a standard addition in the high-risk setting to improve outcomes. The germline `BRCA1` mutation signifies a deficiency in DNA repair, creating a specific vulnerability to PARP inhibitors. The node-positive status elevates the patient's risk of recurrence, making her a candidate for more intensive adjuvant therapy, including consideration of the PARP inhibitor olaparib as established in the OlympiA trial.\\n\\n3. Treatment Options\\n| Event | Treatment | Evidence | Evidence Summary | Previous Response | Warnings |\\n| :--- | :--- | :--- | :--- | :--- | :--- |\\n| **Germline BRCA1 Mutation** | Olaparib (adjuvant) | **OlympiA Trial** - Tuttle et al., 2021; Geyer et al., 2022 [NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa2105215) [PMID: 34111394]; [Lancet Oncology](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00412-6/fulltext) [PMID: 35944577] | Adjuvant olaparib for 1 year in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer showed significantly improved invasive disease-free survival (IDFS) and overall survival (OS). | Not Applicable | Anemia, nausea, fatigue, neutropenia. Small risk of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML). |\\n| **ER+/PR+ Status** | Aromatase Inhibitor + Abemaciclib | **monarchE Trial** - Johnston et al., 2020 [JCO](https://ascopubs.org/doi/full/10.1200/JCO.20.02514) [PMID: 32955575] | In high-risk, node-positive, HR+/HER2- early breast cancer, adding 2 years of adjuvant abemaciclib to endocrine therapy significantly improved IDFS. | Not Applicable | Diarrhea is very common and can be dose-limiting. Neutropenia, fatigue, risk of venous thromboembolism (VTE). |\\n| **ER+/PR+ Status** | Aromatase Inhibitor (AI) or Tamoxifen | **ATAC & BIG 1-98 Trials** - [Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61625-8/fulltext) [PMID: 19010018] | Landmark trials establishing the efficacy of AIs (anastrozole, letrozole) and tamoxifen in the adjuvant setting, reducing recurrence risk by ~50%. | Not Applicable | AI: Musculoskeletal pain, bone loss. Tamoxifen: Risk of endometrial cancer, VTE. |\\n\\n***\\n**Clinical Perspective:**\\nFor this patient, standard-of-care adjuvant treatment after completion of any necessary chemotherapy and local therapy (surgery/radiation) would involve endocrine therapy. Given her high-risk, node-positive status, the combination of an aromatase inhibitor (assuming she is postmenopausal or will undergo ovarian function suppression) and a CDK4/6 inhibitor like abemaciclib is a strong consideration, based on the monarchE trial data.\\n\\nSeparately, the OlympiA trial provides compelling evidence for 1 year of adjuvant olaparib. The patient meets the trial's eligibility criteria (node-positive disease). Current NCCN guidelines recommend considering olaparib for patients like this. The sequencing is important: olaparib is typically started after completion of chemotherapy and radiation and can be given concurrently with endocrine therapy. The decision between offering abemaciclib vs. olaparib, or how to sequence them, is a complex discussion as there is no direct comparative data. This should be reviewed by a multidisciplinary team, considering the patient's specific risk tolerance and potential toxicity profiles.\\n\\n4. Multi-Target Opportunities\\n| Treatment Combination | Targeted Events | Evidence | Summary |\\n| :--- | :--- | :--- | :--- |\\n| **Aromatase Inhibitor + CDK4/6 Inhibitor (e.g., Abemaciclib)** | ER/PR Signaling, Cell Cycle Progression (CDK4/6) | **monarchE Trial** [PMID: 32955575] | This is a standard-of-care combination for high-risk HR+/HER2- early breast cancer. It dually blocks the hormonal driver of cancer growth and the cell cycle machinery, preventing proliferation. |\\n| **Endocrine Therapy + Olaparib** | ER/PR Signaling, Deficient DNA Repair (BRCA1) | **OlympiA Trial** [PMID: 34111394] | In the OlympiA trial, olaparib was administered concurrently with standard endocrine therapy. This approach targets two independent vulnerabilities of the cancer cell simultaneously. |\\n\\n***\\n**Analysis:**\\nThe most evidence-based strategies for this patient involve leveraging both of her tumor's vulnerabilities. The combination of endocrine therapy with a CDK4/6 inhibitor is a well-established, guideline-endorsed approach for high-risk HR+ disease. The addition of a PARP inhibitor is also strongly supported by Level 1 evidence from the OlympiA trial.\\n\\nAs there is no direct evidence comparing (Endocrine Therapy + Abemaciclib) vs. (Endocrine Therapy + Olaparib) in a BRCA-mutated population, the decision requires careful clinical judgment. Many institutions would prioritize the PARP inhibitor given the profound survival benefit seen in OlympiA for this specific genetic subgroup. The combination of endocrine therapy and olaparib is well-tolerated and targets the foundational genetic vulnerability of this patient's cancer.\\n\\n***\\n\\n### Disclaimer\\nThis report is for informational and research purposes only and is not a substitute for professional medical advice. The information provided should be reviewed and discussed by a qualified multidisciplinary tumor board and the patient's treating clinician to determine the most appropriate and individualized treatment plan.\"}],\"role\":null},\"intermediate_data\":{\"tool_uses\":[],\"intermediate_responses\":[]},\"creation_timestamp\":1754690980.953209},\"eval_metric_results\":[{\"metric_name\":\"tool_trajectory_avg_score\",\"threshold\":0.4,\"judge_model_options\":null,\"score\":1.0,\"eval_status\":1},{\"metric_name\":\"response_match_score\",\"threshold\":0.4,\"judge_model_options\":null,\"score\":0.6616871704745166,\"eval_status\":1}]}],\"session_id\":\"___eval___session___43767a97-d3ce-4543-99ee-b50617e8594d\",\"session_details\":{\"id\":\"___eval___session___43767a97-d3ce-4543-99ee-b50617e8594d\",\"app_name\":\"capricorn_adk_agent\",\"user_id\":\"user\",\"state\":{},\"events\":[{\"content\":{\"parts\":[{\"video_metadata\":null,\"thought\":null,\"inline_data\":null,\"file_data\":null,\"thought_signature\":null,\"code_execution_result\":null,\"executable_code\":null,\"function_call\":null,\"function_response\":null,\"text\":\"45-year-old female with invasive\\nductal carcinoma, ER+/PR+/HER2-,\\nBRCA1 mutation, T2N1M0\"}],\"role\":\"user\"},\"grounding_metadata\":null,\"partial\":null,\"turn_complete\":null,\"error_code\":null,\"error_message\":null,\"interrupted\":null,\"custom_metadata\":null,\"usage_metadata\":null,\"live_session_resumption_update\":null,\"invocation_id\":\"e-491754ee-4b07-4f17-982e-cb9af50246db\",\"author\":\"user\",\"actions\":{\"skip_summarization\":null,\"state_delta\":{},\"artifact_delta\":{},\"transfer_to_agent\":null,\"escalate\":null,\"requested_auth_configs\":{}},\"long_running_tool_ids\":null,\"branch\":null,\"id\":\"d730744c-0028-4414-98b1-83678c41f033\",\"timestamp\":1754693401.061505},{\"content\":{\"parts\":[{\"video_metadata\":null,\"thought\":null,\"inline_data\":null,\"file_data\":null,\"thought_signature\":\"CuEaAVSoXO6aRzHoQqC1nwf_Pgak7SX0Uh_a2HisGbZdrLPEkrl54xLe-ruJPqIBIpvAYqTXcWmMOQ16gYKEKQWNaOgKIa8CJr3V6ejuMBspKD0OSkiKlgQA1LLd52JKXYV5tx2YFybmieTmcLFmyPNhNbvfxww25fOuG90uRvWM8KdqsPcPMKFRQ7-2iv8dxckPO_kBj2CDisJurFkinbKox2pSz419zbeKUKbp6zkKShaKzgBh1SaZtFv_njHMIwwmah6pn5usUQwLfCPonun7EA4ChYdQaksSN03_EMoiCfqAXh-kEkwPM6DlVzE8JJdjCU2dc-W0RhlM68JK-CWgs7RDz7z6ABPjV5yyyoW79LTAlIvfwDvKD7-BjFwlSPZ0I1wzgMoya8d6jf9ZrTOfmxxfHJmWK_9IApB3XdMfv88yMOCj-LjUD4JulvNtgi4rcaGmjAXU-kmFkEp7yVXewrqZ-OZfsPLXKeUFRJ2sn-v6M-1Rp_K3xlXrM6qBGlbGedtyamqzXVDyS-ws-7oL2dMd2TwIu-_WIqzHWi2vCwu6eQyime6i7PJfqZ8Bn4DC2nQ-LYHxLTeuVuCTBAN8fHBeopUZSNFWIpkfYEi65tepzEpHwAMeZybsjtlk2S4WvXR-pRno_vh3r3ulNq8BG94wsqX-H6IOR7tOPTS2aBLTHXvu0il5YGhLO0NlIHXx31KaP5QkGlx9S3LERMGoCnwzJSeM-OZi9hC2G546Xhf0ZryIKmuwsGD9wMEAWGz7szzwFXrGiP_TXXWN_h4J9PS_3ZHNMXxLlCVIr6xcwLWVVUk22PHgHzrmzfouhfTFrs8HpoYrkvdMiNebDseZS81mWzTWx6HyYEaxjBZtmmZ-3uRHA3ST1ylqOBTMoGpvJWjRbpW1jzcSuS5GlRqpv7ArQu0tu6LeZUMup-_9XTE1KKJo-uUM4pAAUdH-HuLMIbDa0Q6gvIgBq7Jp03n3DtH00f2SIC8P-490WQipLXnyKt1ChtvJS-eHZZv-t0kgEAZ6cYF6RYnfUuxOOQMqosukSGs6z2NLEy4nLM_CZPrOOrnQSeHUYYAQuhr6Kfp_mhRZsY-vmcKdZ4U4j6XK0srapCP5C91HuP1pz-_NLzUaO7rz3AU35KzcMlsPoBWnJuQDWpOnygEu62TM8NQDRLPw44xuBNZQBpJFex9YUjZzyfrxrFH98CJuoQjI3HC93VMKdOb7WA-YrutA2eXvvw4ERrKik7J2KhtkkFVUNMZgIoY7B1txrkWnpQD3FaIhWjz6xdVNx5ldcfMTXc_QNp1IdwmMiityjRAux9CRv5T8V8xOyGqkeVXZXHA83cCE4xt0gxTl1X5UjtZ8EsJHRw9FugTP9mtn5ljNLVYmhlTGamV6u_UwXq-RlcUsgXSvvwik4S0xTM9_2Nr94zLkYYYv49k8fvIBa7i8twxjJ5_4pNDPidoA4I4nvymbUL9d0h9rAFjyUFvrjyNDkhhduq429D7gyMFVUxVOSnYRp_lfyO54x-A3bvucYFmiuWru_BkDqhk7ZHMCcWfDNyEOhJRuD1dkKe12PZr4fhy7eMkWp0Mqnnnb0nIO6cON5Hb2yfRxlOopC8tV30PM_px3Aw5oMSd0sayxM-0H5msNjxnMBKfW9LoCkhSBKkGklNG-LQ_3PJEtxZXTkyQAhHLxWE8kx1mJQ4ahTfdlaJ2VtSdbLCPcRSDPi3ekxdF63zS-swRG_-ca8hCoGFUU1U4Xi8pednWDKMWbdvo-PNxrgyLYJVRkdM4aHa44NvBg800P1Tp52HzSmPcERdNHXtWE7LUHiQwnHhANRkJ7v_3cFFv0xf-3-QMUbMnUcnDOOLJGm7dS-SBBMg-9pozCf7TWwUE-HedkwetEy78DAM4_tSQ3DDu9Y6sVSyxhr2u8k40p-EfQbkStPniWfzpizPqWF7jkZOX-xE3gp22TFsyRsrX2-l-bvXxroBkRR0pwDnE038H7dtt0klwXwNdKIoG0kXxqFbPG9u73Mg87nvZa5sFe4Ia09nmXDGJQbKSi47Qnne52Flv-e6wBH6K-fqi73S7xV8t54omDZdgBMbaQtLic4uOrAwcmXA0mMem-j_FXswm5NLtZjqOEInd3S2AGvIreHr5zVbN8J-UmYlU6Lkro-n18OW7S12kEBe6REd4Lcdy5J4tLCqRZ419Mqv2h6p6O9dbvGcnaceuwugsJ1yklTsnTiAXSwoTSHQ9k74uF3OxWZMNwxosHjgheie-Yevy1sOIRTBfTOjV9sjiHvlxIa0bF9KEGX6jE1g0PUB_E8TWoNAungIzeqP-3Y6xZgSjepFufpX2eFIX3KKJt-Eagu1oSQViGObh4omeaYpXFs2MImXioGm8BjGm-1KkdxdnhzoNJUtQRvY6f6OaFBikuvfiUxNyu3tnaetASmV3NNt_dLdru8IIDeP9N_q3pWBWsolx4pa_uLmeslXOXkoEvGkLOyBeaE5hB7kPWqSXhob0PTJUIfCSW5433WJW7ouTzp6ZO-j3TwYfgKzi5tfrpHyXxD--xL5EJc3cTY2v4h8jezUPsQDBH2x46Yxf-dOFokaq4gBitulJd1QpVnVS943Y0Tmfr-ne6sY1FfAolVXLTemM-J6grzFiYSXXKvdCY7NU8qX1nmASgWkwmPvv0OhNnTCBQU893IdybBeIQP8poKC8KfLUauxEAQbP292ebIIA1BjiVVb1d3MvhJTi6rm9vfkaMMX23T1WfoI4u0Wv-aKnDDXrMVFivSFaDE8nuapcui0KqraEeUNrL72TRsapTe9Olc36u8x1VyCcWtc3SxuOm4HCah_v1KHTpnvZUnQxwJ1u8-T6Qpab_8yxaeNlZrhETGk2vFl9Q1xCRBOWVXP95LaUjnjKsZaxkJZ3RgbZWADb6WIQbuuRa6ISaAebJj22Jd5N7mQDyduXXX868ipDabT2r0mIWYVTo4ZiEaZ8JEPX89zACeksz724FcNNN5ZoWnItuuUB6k8gKSPGy1t1jD7PKIlZ9XOrA54OXS9JUNh5SDSY4QVjD2LjG1pbCBry8MsmIo9CuifPD714CDSMHq8MH7E87Z33gTkvU7pVixR2HK53C8339gnXf5fulcjtmgIhFZ34wZgdeCx68wcN6goS5lcEainMcmFKoqvMLeVbtmWE5RJySMJCIqiuL2QwznZyh2whhTMLb6ggM4_fJnfwKvLrdXEYHIVIYO4GOfkMjilSrrOK61pdMt0IQfcz39tr0Y7PQ8aQJgHPUZrdFl8R5cwGQi7BYEO8jZVk8PpzhZbDN113GGcZGjka8AmqUZNbvmrrV-qq3f7u6rwlAeV6Es7QwnfgDRE8zC9-06inXAL4tpW98kqYsZ5oOn5hvztHy6xPqaYE0tKwVMliq1TBTzpI9Ar_ZtY0am7yOitCJ2d1J7G7mFo3dKJng6ww5YiqM7EKXpReIXKgksq6S_kcsyL5781TOuguapVshAEe3DZTICJ5s5DzBJtYcMbA8up5RXkKjO6fPcA7HKzyfCemONLbNUcmabHmLsIXHAvRGxnWmpH061J_dL00RUd_QpF4X8uuhELSu87LYHzIOGT35lKRb6sGlijSefTZ1jdiCDdVAZ2nsonn8VWFVTZ_3lJOTvpGrQCFZ9Y7ISiuTTB5M9wpUVCh2z8sduXrGN0r8T_q8qeBdCssJBr-a8cASCNMH-W1NHOmqEYS-EMH-KivEPRRONrzbKAocunDLhM3ERqoANXDpRZjmWDU_AMRhvGK1kyyNEqBXMpE6LG7r9CAEomBU8-7XRqkYde-TybfQ9nJnYGBtXM9wHDMlKhU6d4CxZD7PWNykPKh-i1RABv5RWG_3VlPDLUAgQEZV1ImbqzGw6gJQlPvQlXx5N_2k5wLnNTCYPx4TWpE9PusIeIQColzpQqpL9CIexHK-xEUDNS_6iCXyBw8ZeC1gYV-MoCE66hd4LmPHgt1714c7B-IYFENxpG1shk3G1iK1V4T_aqr5onZCGsuApLpjarum7ckHQJEnkP6sOcRdLOfKh7Jixzg038ndF1v_N_xsq2HqOTxfbelLBXcBcxFNyh8lvj4G_wOFJph6FC5J-28ZlnEOAZhLMBRxOTC1V8Royo4-BvUOPe_ajQmpcrRGJNgSdZ182KWAY64ypsNbsr9UQB80G7Bgix1TyOpXopJ__tA82Ag3AvG0jgevUggoOFoCFlymzTt6tRAsCRbPbvZZdzvxBsk1LEARXLkdMAw5URHYGdE4kF6-8okK3Py70pVDd_EKWVcLO9w6JQIYd42Mou4TYbWR-ADKi-yAwTpr4dasngOWHAr67M5Ck79zGoI8GIrk0uW_QjgxjRxCNCLM6v0PpIyR6HHh6LimJqvHNZIId7Z0NKuaEbgD-wz657UkidsjgljdPPfPkhPD9XcchiisCplmuFWnFMoFUJ4aigOYg2YuC4U8BKbofxCIN_k-i3fwcZSeL1YO7UKdImLxUrVTfZBqng-2LTqtCyZBpEaFcVM2OYT8GAHgmsRUBYpwX01oj5PQ68Fs9evFGQkp4Ipzhpw0Iny2r9M=\",\"code_execution_result\":null,\"executable_code\":null,\"function_call\":null,\"function_response\":null,\"text\":\"Analysis Results\\nCase Analysis: Stage IIB, ER+/PR+/HER2- Invasive Ductal Carcinoma with Germline BRCA1 Mutation\\n1. Case Summary\\nThe patient is a 45-year-old female diagnosed with Stage IIB (T2N1M0) invasive ductal carcinoma of the breast. The tumor is hormone receptor-positive (ER+/PR+) and HER2-negative. Germline genetic testing revealed a pathogenic mutation in the BRCA1 gene. This combination of factors (hormone sensitivity, DNA repair deficiency via BRCA1 mutation, and node-positive disease) provides multiple avenues for targeted adjuvant therapy aimed at reducing the risk of recurrence.\\n\\n2. Actionable Events Analysis\\n| EventType | Genetic/Clinical | Explanation | Targetable | Prognostic Value |\\n| :--- | :--- | :--- | :--- | :--- |\\n| **ER/PR Positive** | Clinical | The tumor expresses estrogen and progesterone receptors, indicating that its growth is driven by hormones. | Yes, with endocrine therapy (e.g., Aromatase Inhibitors, SERMs, OFS). | Favorable; predicts benefit from endocrine therapy. |\\n| **Germline BRCA1 Mutation** | Genetic | A pathogenic mutation in the BRCA1 gene impairs the homologous recombination repair (HRR) pathway for DNA damage. | Yes, with PARP inhibitors (e.g., Olaparib). | Unfavorable; associated with higher risk of recurrence and new primary cancers (breast, ovarian). Predicts sensitivity to PARP inhibitors and platinum-based chemotherapy. |\\n| **N1 (Node Positive)** | Clinical | Presence of cancer in 1-3 axillary lymph nodes, indicating regional spread. | Yes, indicates need for systemic adjuvant therapy (chemotherapy, targeted therapy). | Unfavorable; a key indicator of higher recurrence risk, justifying more aggressive adjuvant treatment. |\\n\\n***\\n\\n**Interpretation:** This is a high-risk, localized breast cancer defined by two key targetable biological features. The ER/PR positivity makes the cancer susceptible to hormone-blocking agents, a cornerstone of therapy. The germline BRCA1 mutation creates a specific vulnerability in the tumor's DNA repair machinery, which can be exploited by PARP inhibitors. The node-positive status (N1) elevates the risk of recurrence and confirms the need for comprehensive adjuvant systemic therapy, including chemotherapy, to be followed by targeted agents. The treatment strategy must address both the hormone-driven growth and the underlying DNA repair defect.\\n\\n3. Treatment Options\\n| Event | Treatment | Evidence | Evidence Summary | Previous Response | Warnings |\\n| :--- | :--- | :--- | :--- | :--- | :--- |\\n| **Germline BRCA1 Mutation** | Adjuvant Olaparib | [Tutt ANJ et al., 2021 [PubMed](https://pubmed.ncbi.nlm.nih.gov/34115795/)] | The Phase 3 OlympiA trial showed that for patients with germline BRCA1/2 mutations and high-risk HER2- early breast cancer, 1 year of adjuvant olaparib after (neo)adjuvant chemotherapy and local treatment significantly improved invasive and distant disease-free survival compared to placebo. At 3.5 years, the invasive disease-free survival was 82.7% vs. 75.4%. | N/A (adjuvant setting) | Anemia, neutropenia, fatigue, nausea. Small risk of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). |\\n| **ER/PR Positive** | Endocrine Therapy (e.g., Aromatase Inhibitor or Tamoxifen) + Ovarian Function Suppression (OFS) | [Francis PA et al., 2018 [PubMed](https://pubmed.ncbi.nlm.nih.gov/30575488/)] | The SOFT and TEXT trials demonstrated that for premenopausal women, adding OFS to either tamoxifen or an aromatase inhibitor (exemestane) significantly improved disease-free survival compared to tamoxifen alone. The benefit was most pronounced in patients who required chemotherapy, such as this one. | N/A (adjuvant setting) | Menopausal symptoms (hot flashes, vaginal dryness), arthralgias (with AIs), risk of endometrial cancer and VTE (with tamoxifen), bone density loss. |\\n| **ER/PR Positive & High-Risk Features (N1)** | Adjuvant Abemaciclib + Endocrine Therapy | [Johnston SRD et al., 2023 [PubMed](https://pubmed.ncbi.nlm.nih.gov/36877088/)] | The Phase 3 monarchE trial showed that for patients with high-risk, node-positive, HR+/HER2- early breast cancer, adding 2 years of abemaciclib to standard endocrine therapy significantly improved invasive disease-free and distant relapse-free survival. At 4 years, the absolute benefit in IDFS was 6.4%. | N/A (adjuvant setting) | Diarrhea, neutropenia, fatigue, abdominal pain, liver enzyme elevation. Requires monitoring of blood counts and liver function. |\\n\\n***\\n\\n**Clinical Perspective:** The standard of care for this patient involves a multimodal adjuvant approach following definitive surgery and likely anthracycline/taxane-based chemotherapy. Based on the landmark OlympiA trial, one year of adjuvant olaparib is strongly recommended to target the BRCA1-mutated cancer cells. Concurrently and sequentially, endocrine therapy is critical. Given the patient's age (45, likely premenopausal) and high-risk status, ovarian function suppression combined with an aromatase inhibitor would be a standard and effective endocrine backbone. The role of adjuvant abemaciclib is also a key consideration. While the patient meets the node-positive criterion for monarchE, guidelines suggest choosing between a PARP inhibitor or a CDK4/6 inhibitor in this setting, as concurrent use outside of a clinical trial is not established. Given the germline BRCA1 mutation is a powerful oncogenic driver, prioritizing olaparib is a very common and evidence-based strategy.\\n\\n4. Multi-Target Opportunities\\n| Treatment Combination | Targeted Events | Evidence | Summary |\\n| :--- | :--- | :--- | :--- |\\n| **Olaparib (Adjuvant) + Endocrine Therapy + OFS** | Germline BRCA1 Mutation, ER/PR Positive status | [Tutt ANJ et al., 2021 [PubMed](https://pubmed.ncbi.nlm.nih.gov/34115795/)], [Francis PA et al., 2018 [PubMed](https://pubmed.ncbi.nlm.nih.gov/30575488/)] | This represents the standard-of-care, evidence-based adjuvant regimen. Olaparib targets the DNA repair deficiency, while endocrine therapy with OFS suppresses the hormonal growth signals. These treatments have different mechanisms of action and address the two main vulnerabilities of the tumor. |\\n| **Abemaciclib (Adjuvant) + Endocrine Therapy + OFS** | ER/PR Positive status, High-Risk (N1) | [Johnston SRD et al., 2023 [PubMed](https://pubmed.ncbi.nlm.nih.gov/36877088/)] | This is an alternative high-intensity adjuvant regimen. Abemaciclib targets the cell cycle by inhibiting CDK4/6, which is often dysregulated in ER+ breast cancer. This would be a primary consideration if the patient did not have a BRCA1 mutation. |\\n\\n***\\n\\n**Analysis:** The most rational and evidence-based strategy is to combine therapies that target the distinct biological drivers of this cancer. The combination of adjuvant olaparib with endocrine therapy (with OFS) is well-supported by Level 1 evidence from separate, large, randomized clinical trials. Olaparib addresses the germline-driven risk, while endocrine therapy addresses the hormone-driven risk. There is no high-level evidence to support the concurrent use of olaparib and abemaciclib in the adjuvant setting, and the potential for overlapping toxicities (e.g., hematologic) would be a significant concern. Therefore, the decision is typically a choice between these two agents to add to the endocrine backbone. In a BRCA1-mutated patient, olaparib is the more direct and targeted approach.\\n\\n***\\n\\n### References\\n\\n1.  Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., ... & Roch\u00e9, H. (2021). Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. *New England Journal of Medicine*, *384*(25), 2394\u20132405. [PMID: 34115795](https://pubmed.ncbi.nlm.nih.gov/34115795/)\\n2.  Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M., L\u00e1ng, I., ... & SOFT and TEXT Investigators and the International Breast Cancer Study Group. (2018). Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. *New England Journal of Medicine*, *379*(2), 122-137. [PMID: 30575488](https://pubmed.ncbi.nlm.nih.gov/30575488/)\\n3.  Johnston, S. R. D., Toi, M., O'Shaughnessy, J., Rastogi, P., a Comet, A., Prito, B., ... & monarchE Committee Members. (2023). Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer: results from a preplanned overall survival interim analysis of the monarchE trial. *The Lancet Oncology*, *24*(1), 77\u201390. [PMID: 36877088](https://pubmed.ncbi.nlm.nih.gov/36877088/)\\n\\n***\\n\\n**Disclaimer:** This report is for informational and research purposes only and does not constitute medical advice. The information provided is based on the patient data supplied and a review of current medical literature and guidelines. All clinical decisions must be made by a qualified clinician in the context of a multidisciplinary tumor board review, taking into account the full clinical picture and the patient's individual circumstances and preferences.\"}],\"role\":\"model\"},\"grounding_metadata\":null,\"partial\":null,\"turn_complete\":null,\"error_code\":null,\"error_message\":null,\"interrupted\":null,\"custom_metadata\":null,\"usage_metadata\":{\"cache_tokens_details\":null,\"cached_content_token_count\":null,\"candidates_token_count\":2281,\"candidates_tokens_details\":null,\"prompt_token_count\":1319,\"prompt_tokens_details\":[{\"modality\":\"TEXT\",\"token_count\":1319}],\"thoughts_token_count\":859,\"tool_use_prompt_token_count\":null,\"tool_use_prompt_tokens_details\":null,\"total_token_count\":4459,\"traffic_type\":null},\"live_session_resumption_update\":null,\"invocation_id\":\"e-491754ee-4b07-4f17-982e-cb9af50246db\",\"author\":\"capricorn_medical_oncology_agent\",\"actions\":{\"skip_summarization\":null,\"state_delta\":{},\"artifact_delta\":{},\"transfer_to_agent\":null,\"escalate\":null,\"requested_auth_configs\":{}},\"long_running_tool_ids\":null,\"branch\":null,\"id\":\"a47b740e-f839-4f99-95dd-dc66469ecaec\",\"timestamp\":1754693401.061756}],\"last_update_time\":1754693401.061756},\"user_id\":\"user\"}],\"creation_timestamp\":1754693698.710449}"